Table 3. Prognostic factor analysis for overall response.
| Characteristic | Response | P-value‡ | Odds ratio | 95% CI | P-value* | ||
|---|---|---|---|---|---|---|---|
| n/N | (%) | Lower | Upper | ||||
| Age, years | 0.7925 | ||||||
| ≤65 | 46/72 | (63.89%) | 0.7924 | 1 | |||
| >65 | 37/60 | (61.67%) | 0.909 | 0.448 | 1.847 | ||
| Sex | 0.7740 | ||||||
| Male | 47/76 | (61.84%) | 0.774 | 1 | |||
| Female | 36/56 | (64.29%) | 1.111 | 0.543 | 2.273 | ||
| Duration of MDS | 0.0985 | ||||||
| ≤ 1 year | 76/116 | (65.52%) | 0.0911 | 1 | |||
| > 1 year | 7/16 | (43.75%) | 0.409 | 0.142 | 1.181 | ||
| WHO subtype | 0.3437 | ||||||
| RCUD | 1/4 | (25.00%) | 0.2 | 1 | |||
| RARS | 2/3 | (66.67%) | 6.000 | 0.221 | 162.531 | ||
| RCMD | 22/40 | (55.00%) | 3.667 | 0.351 | 38.345 | ||
| RAEB-1 | 23/30 | (76.67%) | 9.857 | 0.880 | 110.425 | ||
| RAEB-2 | 26/36 | (72.22%) | 7.800 | 0.723 | 84.091 | ||
| MDS-U | 2/6 | (33.33%) | 1.500 | 0.089 | 25.392 | ||
| Del(5q) | 1/1 | (100.00%) | >999.999 | <0.001 | >999.999 | ||
| CMML-1 | 3/7 | (42.86%) | 2.250 | 0.149 | 33.933 | ||
| CMML-2 | 2/2 | (50.00%) | 3.000 | 0.150 | 59.890 | ||
| Unclassified | 1/1 | (100.00%) | >999.999 | <0.001 | >999.999 | ||
| IPSS risk category | 0.5265 | ||||||
| Intermediate-1 | 53/86 | (61.63%) | 0.5062 | 1 | |||
| Intermediate-2 | 22/36 | (61.11%) | 0.978 | 0.440 | 2.175 | ||
| High | 8/10 | (80.00%) | 2.491 | 0.498 | 12.451 | ||
| Karyotype at baseline | 0.0239 | ||||||
| Good (normal or other) | 53/75 | (70.67%) | 0.0191 | 1 | |||
| Intermediate | 11/27 | (40.74%) | 0.285 | 0.114 | 0.712 | 0.0112** | |
| Poor | 15/22 | (68.18%) | 0.890 | 0.319 | 2.481 | 0.3211** | |
CMML, chronic myelomonocytic leukemia; CR, complete response; Del, deletion; HI, hematologic improvement; IPSS, International Prognostic Scoring System; mCR, marrow complete response; MDS, myelodysplastic syndrome; MDS-U, unclassifiable MDS; ORR, overall response rate; PR, partial response; RAEB, refractory anemia with excess of blasts; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia
*
P-value is obtained by logistic regression (Wald test – testing global null hypothesis)
**
P-value is obtained by logistic regression
‡
P-value is obtained by Chi-square test